2seventy bio, Inc. (TSVT) Financial Analysis & Valuation | Quarter Chart
2seventy bio, Inc., a cell and gene therapy company, focuses on the research, development, and commercialization of treatments for cancer in the United States. Its products pipeline includes idecabtagene vicleucel; ide-cel or Abecma and bb21217; and CAR-T cell product candidates for the treatment of... more
2seventy bio, Inc., a cell and gene therapy company, focuses on the research, development, and comme... more
Company facts
Reported company information and share structure.
Company
Share structure
| Market Cap | $266.14M | Exchange | NASDAQ |
| Sector | Healthcare | Industry | Biotechnology |
| Country | US | CEO | William D. Baird III, |
| IPO Date | 2021-11-03 | CAGR | -5.91% |
| Employees | 65 | Website | www.2seventybio.com |
| Div. Yield | — | Payout Ratio | — |
| Buy Back Yield | — | Total Yield | — |
TSVT chart loading...
Key metrics
Reported fundamentals and market-derived technical indicators.
Fundamentals
Technicals
| EV | $409.50M | P/E | -62.5 | Forward P/E | — | PEG | — |
| P/S | 10.29 | P/B | 1.24 | P/CF | -12.97 | P/FCF | -13.02 |
| Sales | $48.37M | Sales 1Y | -32.07% | Sales 3Y | -5.25% | Sales 5Y | — |
| EPS | $-0.08 | EPS 1Y | — | EPS 3Y | — | EPS 5Y | — |
| Sales QoQ | 683.94% | EPS QoQ | -102.46% | Sales QoQ Avg | 157.15% | EPS QoQ Avg | -73.62% |
| Gross Margin | 45.89% | Operating Margin | -99.7% | Profit Margin | -73.61% | ROCE | -5.88% |
| ROA | -4% | ROE | -9% | Altman Z Score | -0.97 | Piotroski Score | 2 |
| Current Ratio | 4.8 | Quick Ratio | 4.8 | Cash Ratio | 2.23 | Op. CF Ratio | -0.27 |
| Debt/Equity | 1.12 | Debt/Assets | 0.5 | Lt Debt/Equity | 1.04 | Lt Debt/Cap. | — |
| Intrst Cov. | — | Inventory Turnover | — | Asset Turnover | 0.05 | Receivables Turnover | 1.08 |
| Enterprise Value | $409.50M | P/E Ratio | -62.5 |
| Forward P/E | — | PEG Ratio | — |
| P/S Ratio | 10.29 | P/B Ratio | 1.24 |
| P/CF Ratio | -12.97 | P/FCF Ratio | -13.02 |
| EPS | $-0.08 | EPS Growth 1Y | — |
| EPS Growth 3Y | — | EPS Growth 5Y | — |
| Revenue Growth 1Y | -32.07% | Gross Margin | 45.89% |
| Operating Margin | -99.7% | Profit Margin | -73.61% |
| ROE | -9% | ROA | -4% |
| ROCE | -5.88% | Current Ratio | 4.8 |
| Quick Ratio | 4.8 | Cash Ratio | 2.23 |
| Debt/Equity | 1.12 | Interest Coverage | — |
| Altman Z Score | -0.97 | Piotroski Score | 2 |
2seventy bio, Inc. (TSVT) valuation & financials
2seventy bio, Inc. (TSVT) has a market capitalization of $266.14M and trades at a price-to-earnings ratio of -62.5. It operates in the Healthcare sector (Biotechnology).
2seventy bio, Inc.'s revenue grew -32.1% over the last year.
Compare with other Healthcare companies: Eli Lilly (LLY) · Johnson & Johnson (JNJ) · AbbVie (ABBV) · Merck (MRK) · UnitedHealth (UNH) · Roche (ROG.SW)